Know Labs, a developer of non-invasive diagnostics technology, announced that it received a notice from NYSE American on September 27, 2024, stating it is no longer compliant with continued listing standards. Specifically, the company does not meet the stockholders’ equity requirements outlined in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide.
The notice does not immediately affect the trading of Know Labs’ common stock, which will continue to be listed under the symbol “KNW,” but will carry a “.BC” designation to indicate it is “below compliance.” The company must submit a compliance plan by October 27, 2024, detailing how it will regain compliance by March 27, 2026.
If accepted, the plan will allow Know Labs to maintain its listing while undergoing periodic reviews by NYSE American staff. Should the plan be rejected or if compliance is not achieved by the deadline, Know Labs could face delisting procedures.
The company aims to enhance its business and technological development and anticipates making positive announcements regarding strategic partnerships to support its efforts. However, there is no guarantee that compliance will be achieved within the required timeframe.
About Know Labs, Inc.
Know Labs trades on the NYSE American under “KNW” and focuses on using spectroscopy for non-invasive diagnostics. Its first anticipated product is a non-invasive glucose monitor, pending FDA clearance.
Safe Harbor Statement
This release contains forward-looking statements regarding Know Labs’ future performance and strategies, which involve risks and uncertainties. Actual results may differ materially. For more details, please refer to the company’s filings with the SEC available on its website.
